In another clinical trial involving NSCLC, melanoma, renal cell carcinoma, etc., a response to atezolizumab has more frequently been observed in patients expressing high levels of PD-L1 in tumors, especially when PD-L1 is expressed in TILs (Herbst et al., 2014). Here, CD274 is linked to melanoma.